Categroies

Categroies
Home
/
Categroies
/
API
/
Antitumor
/
Dabrafenib
1/1
Number of views:
1000

Dabrafenib

is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E mutation detected by an FDA-approved test.
Retail price
0.0
元
Market price
0.0
元
Number of views:
1000
Product serial number
Category
Antitumor
Related products Inquiry
Quantity
-
+
Stock:
0
1
Details
Cas No.:
1195768-06-9
Indication:

is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E mutation detected by an FDA-approved test.

is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E mutation detected by an FDA-approved test.

We could not find any corresponding parameters, please add them to the properties table
Previous
Sorafenib tosylate
Next
Regorafenib

keyword：Chemical products，Chinese medicine products

Related products

Sorafenib tosylate
Sorafenib tosylate
Dabrafenib
Dabrafenib
Sitagliptin phosphate
Sitagliptin phosphate
Regorafenib
Regorafenib

Inquiry

Huafang Pharmceutical Sciences

Hotline：0551-65551391

Fax：0551-65336396

Add： Building D-5, Technology Industrial Park, 168 Xiangzhang Avenue, National High-tech Zone, Hefei City

Huafang

Wechat

Huafang

Mobile

Copyright © Huafang Pharmceutical

Verification 皖ICP备10206584号-1
Sitemap
Market
Job
Team spirit
Honor
Public welfare
Company News
Copyright